What might CSL shares be faced with in November?

Time to saddle up for the second last month of the year. Here's a peek at the points of interest for CSL in November.

| More on:
Shot of a scientist using a computer while conducting research in a laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A new month is underway for CSL Limited (ASX: CSL) shares today after an abysmal October for the biotech heavyweight. At the end of yesterday, Australia's third most valuable listed company tallied up a monthly share price decline of 7.4%, settling at $232.35.

The tenth month of 2023 was unkind to other ASX healthcare shares (and markets more broadly) as well, with stalwarts, such as Cochlear Limited (ASX: COH) and Sonic Healthcare Ltd (ASX: SHL), suffering decreases in share price.

In any event, CSL shares were tenderised last month, arguably led by speculation around weight-loss drugs. The question is then: what could be awaiting shareholders this month?

The month ahead for CSL shares

For those CSL investors who can appreciate quieter times, you could be in luck.

The past few months have been almost non-stop action at the plasma medical products company.

In August, investors were supplied with the latest full-year results. Then, CSL shares went ex-dividend in September. Finally, October gave rise to the fluster from new research showing possible uses of semaglutide in chronic kidney disease — as well as capital markets day to boot.

In contrast, the November schedule is entirely uneventful. No dividend dates, no annual general meeting, and no quarterly results. Does that mean we won't hear a peep from anyone about CSL shares? Maybe… though, it is unlikely.

It's fair to say that weight-loss drugs have the investing world captivated. Every person and their dog are vigorously trying to establish the next area of disruption caused by GLP-1 receptor agonists, such as Ozempic.

Findings of a safety review conducted by the European Medicines Agency (EMA) into GLP-1s are expected this month. The medical body has decided to see whether there is any causal relationship following a number of reports of "suicidal thoughts and self-injury" among people taking the medicine.

Notably, the EMA determined on 27 October 2023 that there was no supporting link between GLP-1 drugs and thyroid cancer. The review was prompted by a publication in 2022 suggesting a possible increased risk among people taking GLP-1 agonists for type 2 diabetes.

There's a good chance investors will be on the lookout for information relating to the drug's application in medical areas where CSL operates.

Beyond this month

Looking further out than November, a handful of analysts expect upside to CSL shares.

Now trading on a price-to-earnings (P/E) ratio of around 33 times, is the biotech company 'cheap'? Marcus Today analyst Matt Lattin considers it a buy, referencing improving gross margins and a diverse strategy.

CSL expects to grow its net profit after tax (NPAT) by between 13% to 17% in FY2024. At the midpoint, this would value CSL shares at approximately 24 times FY24 earnings.

Motley Fool contributor Mitchell Lawler has positions in Sonic Healthcare. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Cochlear. The Motley Fool Australia has recommended CSL, Cochlear, and Sonic Healthcare. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Scientist with headache, stress and fatigue with woman, overworked with overtime for science breakthrough. Medical research, scientific innovation and senior female, burnout and migraine in lab.
Healthcare Shares

Why is the Mesoblast share price in a trading halt?

Is Mesoblast raising funds again? Let's find out.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

The CSL share price return tripled the ASX 200 in November

November saw a very healthy return for CSL shares.

Read more »

A male doctor wearing a white doctor's coat shrugs and holds his hands up to indicate the unimpressive CSL share price as a result of OOVID-19
Share Market News

Here's why you might have just bought Healius shares

Two of the most popular super funds just loaded up on this healthcare stock.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Here's why this ASX 200 healthcare stock is roaring 13% higher on Wednesday

This healthcare company is outperforming every other stock within the ASX 200 today.

Read more »

A young woman sits at her desk in deep contemplation with her hand to her chin while seriously considering information she is reading on her laptop

Could CSL stock be a millionaire-maker at $261

Does the exceptional biotech company still harness the power to make an investment today worth a million in the future?

Read more »

Two happy scientists analysing test results in a lab
Healthcare Shares

Why are Mesoblast shares charging 5% higher today?

This beaten down biotech is having a strong session. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Healius share price rallies amid corporate reset

An outgoing chair and a revitalised balance sheet. Healius is undergoing a makeover.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Imugene share price jumps 32% on FDA news

Here's why this biotech is having a strong start to the session.

Read more »